Long Position on BIVV @ $51.50 on 3/14/2017 (Momentum)

Bioverativ Inc. (BIVV) is a biotechnology company.

The firm focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States and Japan.

The company offers ELOCTATE, an antihemophilic factor (recombinant) Fc fusion protein; and ALPROLIX, a coagulation factor IX (recombinant) Fc fusion protein for the treatment of hemophilia A and B.

It markets and sells its products to specialty distributors, specialty pharmacies, hemophilia treatment centers, public and private hospitals, and other government entities. The company has collaboration with Swedish Orphan Biovitrum AB (publ) to develop and commercialize ELOCTATE and ALPROLIX worldwide.

The company was spun off last month by Biogen Inc. (BIIB). Shares of this IPO have formed a bullish "cup and handle" and are expcted to head higher. Please note that the firm does not have any debt, and has $325 million in cash. Please note that the firm is schdeuled to report its quarterly results on March 16th!

52-Weeks Trading Range: $41.88 - $54.20

Entry Point: $51.50

Stop Loss: $48.45

Target Price: $56.65

Updates

4/10/2017 9:44:08 AM

BIVV closed at $57.00

Position closed on 4/10/2017 at price of $57.00 with a 10.68% gain in 27 days.

Back to Portfolio